Antibiotics for exacerbations of chronic obstructive pulmonary disease
87 results
1 - 87
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Antibiotics for exacerbations of chronic obstructive pulmonary disease - Antibiotics for exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review
Improved outcomes with azithromycin vs beta-lactams for acute exacerbations of chronic obstructive pulmonary disease- Antibiotic and corticosteroid treatment effective for acute exacerbations of COPD
- Corticosteroids, selective use of antibiotics and NPPV for COPD exacerbations
- Short-course antibiotics effective for acute exacerbation of COPD
- For mild to severe COPD exacerbations, antibiotics and steroids remain the mainstay of treatment
- C-reactive protein helps reduce antibiotic prescribing for COPD exacerbations
- In high-risk patients with chronic obstructive pulmonary disease, dupilumab slightly reduces moderate exacerbation (BOREAS)
- Sputum purulence and CRP predict poor prognosis with COPD exacerbation
- C-reactive protein guidance safely reduces antibiotic use in patients with acute exacerbation of COPD (NNT = 5)
- Procalcitonin test can reduce antibiotic use in COPD
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
- Amox-clavulanate during COPD exacerbations decreases Sx and delays subsequent exacerbations
- Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
- Methylxanthines for exacerbations of chronic obstructive pulmonary disease
- Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease
- Providing procalcitonin levels does not reduce antibiotic use in patients with lower respiratory tract infections
- One year of once-daily doxycycline does not reduce exacerbation frequency in adults with moderate to severe COPD
- Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease
- Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
- Anticholinergic bronchodilators versus beta2‐sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease
- Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
- Inhaled short‐acting beta2‐agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease
- Action plans for chronic obstructive pulmonary disease
- Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)
- Procalcitonin reduces antibiotic prescribing for acute bronchitis but not other causes of lower respiratory tract infection
- Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta‐analysis
- Haemophilus influenzae vaccination for the prevention of acute exacerbations of chronic bronchitis
- Vitamin D for the management of chronic obstructive pulmonary disease
- Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease: Cochrane systematic review
- Aclidinium bromide for stable chronic obstructive pulmonary disease
- Canadian Thoracic Society guidelines for pharmacotherapy of stable chronic obstructive pulmonary disease
- Short-term antibiotic treatment is suitable for several outpatient infections
- More evidence against antibiotics for acute asthma exacerbations
- Prophylactic antibiotic therapy for chronic obstructive pulmonary disease
- Procalcitonin testing decreases antibiotic use
- Long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review
- Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease
- Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
- Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
- Mepolizumab provides only a small reduction in moderate exacerbations when added to triple inhaler therapy for eosinophilic COPD (MATINEE)
- Fewer exacerbations but somewhat more pneumonia with triple inhaler therapy for COPD (IMPACT)
- Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
- Triple inhaled therapy provides a small reduction in moderate exacerbations, no effect on severe exacerbations (ETHOS)
- Delayed Rx for respiratory infections produces similar results and satisfaction as immediate treatment
- Long-acting beta-2 agonists for chronic obstructive pulmonary disease
- Integrated disease management interventions for patients with chronic obstructive pulmonary disease
- Self‐management for bronchiectasis
- Zinc for the common cold: Cochrane systematic review
- Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections